8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): February 25, 2003


                         Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                England and Wales
- --------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)


         0-29630                                           98-0359573
(Commission File Number)                       (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices)                      (Zip code)

Registrant's telephone number, including area code         44 1256 894 000



- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)







Item 5.  Other Events

     Shire Pharmaceuticals Group plc has issued the press release attached as
Exhibit 99.1 and incorporated by reference herein.

Item 7.  Financial Statements and Exhibits

     (c) Exhibits. The following exhibit is filed herewith:

99.1     Press Release dated February 25, 2003








                                    SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: February 25, 2003


                                  SHIRE PHARMACEUTICALS GROUP PLC

                                  By:    /s/ Angus Charles Russell
                                         ----------------------------------
                                         Name:  Angus Charles Russell
                                         Title:  Group Finance Director








                                  EXHIBIT INDEX


Number   Description

99.1     Press Release dated February 25, 2003

EX-99.1

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP  UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com


7am ET 12 noon GMT
Tuesday 25 February 2003


     SHIRE FILES LEGAL SUIT AGAINST BARR LABORATORIES FOR ADDERALL XRTM ANDA



BASINGSTOKE, UK - 25 FEBRUARY 2003 - Shire Pharmaceuticals Group plc (LSE: SHP,
NASDAQ: SHPGY, TSX: SHQ) announces that its subsidiary Shire Laboratories Inc.
has filed a lawsuit in the US District Court for the Southern District of New
York against Barr Laboratories Inc. ("Barr") for infringement of Shire
Laboratories' U.S. patent No. 6,322,819 ("'819 Patent").

The lawsuit results from an ANDA (Abbreviated New Drug Application) filed by
Barr for a generic version of ADDERALL XR, pursuant to which Barr provided
notice that it would seek to market its generic product before the expiration of
the `819 Patent in 2018. ADDERALL XR is Shire's leading extended release
Attention Deficit Hyperactivity Disorder ("ADHD") medicine.

Barr cannot launch a generic version of ADDERALL XR before it receives final
approval of its ANDA from the FDA. The lawsuit triggers a stay of FDA approval
of up to 30 months from Barr's notice to allow the court to resolve the suit.
Even if Barr receives a final approval from the FDA, it cannot lawfully sell its
generic version without successfully resolving the legal challenge to the Shire
patent.

Says Shire Chief Executive, Rolf Stahel:

"With this lawsuit we are vigorously enforcing our intellectual property. We
will fight this challenge to our issued, valid and enforceable patent which
expires in 2018. Hatch Waxman also provides exclusivity for ADDERALL XR and will
not allow any generic launch until at least October 2004."

                                      ENDS


FOR FURTHER INFORMATION PLEASE CONTACT:

GLOBAL (OUTSIDE US AND CANADA)
Gordon Ngan - Investor Relations                        +44 1256 894 160
Jessica Mann - Media                                    +44 1256 894 280

US & CANADA
Gordon Ngan - Investor Relations                        +44 1256 894 160
Michele Roy - Media                                     +1 450 978 7876




NOTES TO EDITORS

SHIRE PHARMACEUTICALS GROUP PLC

Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international
specialty pharmaceutical company with a strategic focus on four therapeutic
areas - central nervous system disorders (CNS), oncology, gastro-intestinal (GI)
and anti-infectives. Shire also has three platform technologies: advanced drug
delivery, lead optimisation for small molecules and biologics. Shire's core
strategy is based on research and development combined with in licensing and a
focus on eight key pharmaceutical markets.

For further information on Shire, please visit the Company's website:
www.shire.com

THE "SAFE HARBOUR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. The statements made in this press release that are not historical facts
are forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the event
that such risks or uncertainties materialise, Shire's results could be
materially affected. The risks and uncertainties include, but are not limited
to, risks associated with the inherent uncertainty of pharmaceutical research,
product development and commercialisation, the impact of competitive products,
including but not limited to the impact of same on Shire's ADHD franchise of
patents, government regulation and approval, including but not limited to the
expected approval date of lanthanum carbonate (FOSRENOL/FOSNOL) and other risks
and uncertainties detailed from time to time in periodic reports produced by
Shire, including the Annual Report filed on Form 10K by Shire with the
Securities and Exchange Commission.